Drug profile · INN
pipecuronium bromide
ARDUAN
pipecuronium bromide (ARDUAN) is a muscle-type nicotinic acetylcholine receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — pipecuronium bromide
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
pipecuronium bromide (ARDUAN) is a muscle-type nicotinic acetylcholine receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscle-type nicotinic acetylcholine receptor antagonist
Primary target: Muscle-type nicotinic acetylcholine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is pipecuronium bromide?
pipecuronium bromide (ARDUAN) is a muscle-type nicotinic acetylcholine receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for pipecuronium bromide?
ARDUAN is a marketed brand name for pipecuronium bromide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pipecuronium bromide?
pipecuronium bromide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.